Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T18:46:19.147Z.
Calculation as of: 2026-10-06T18:46:19.147Z.
Quote observation: 2026-10-06T18:44:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b5b90a83151b8a074e07f32cd5a8423240b7dae761ecc8f52934664174c7f924
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$33.46M
EV/EBIT Ratio
N/A
TTM Avg
50.30x
3Y Avg
467.13x
5Y Avg
265.91x
Market Cap
$35.86M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Elutia Inc (ELUT) | $34.48M | N/A | N/A | N/A | N/A |
| Grace Therapeutics, Inc. (GRCE)vs › | $34.42M | N/A | N/A | N/A | N/A |
| BriaCell Therapeutics Corp. (BCTX)vs › | $35.19M | N/A | N/A | N/A | N/A |
| HeartBeam, Inc. (BEAT)vs › | $33.71M | N/A | N/A | N/A | N/A |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.29M | N/A | N/A | N/A | N/A |
| Scilex Holding Company (SCLX)vs › | $33.58M | N/A | N/A | N/A | N/A |
| DocGo Inc. (DCGO)vs › | $35.57M | N/A | 8.66x | 44.05x | 43.98x |
| Accuray Incorporated (ARAY)vs › | $33.46M | N/A | 50.30x | 467.13x | 265.91x |
| EUDA Health Holdings Limited (EUDA)vs › | $35.86M | N/A | N/A | N/A | N/A |
| QT Imaging Holdings, Inc. (QTI)vs › | $36.28M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute